Immuno-oncology drugs use the body's immune system to fight cancer, and have demonstrated improved survival rates for various cancer types. These drugs boost the immune response against cancer cells, and thus, improve survival outcomes. Some major immuno-oncology drug classes approved include checkpoint inhibitors, cancer vaccines, and nonspecific immunotherapies. Continued clinical research and development of novel agents with improved efficacy and safety profiles can drive the market growth.

Market Dynamics:

Global immuno-oncology drugs market growth is primarily driven by rising cases of cancer worldwide. Cancer incidence has been rising year-on-year owing to lifestyle changes, increased life expectancy, and environmental factors like pollution. Immuno-oncology drugs have demonstrated long-term efficacy and survival benefits as compared to conventional cancer therapies. This boosts pharmaceutical R&D and increases drug approvals. The developments in companion diagnostics identify patient populations most suitable for immunotherapies, thus, driving the market growth. However, high costs of these drugs can restrict its adoption in price-sensitive regions. Safety issues like immune-related adverse effects can also hamper the market growth. Ongoing clinical trials evaluating new indications, drug combinations, and personalized therapies can offer lucrative opportunities for the market growth in the near future.

Key Features of the Study:

• This report provides in-depth analysis of the global immuno-oncology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Merck, Roche, Pfizer, AstraZeneca, and Novartis
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation-

• By Treatment Type
  
  • Immune Checkpoint Inhibitors 
    
    • PD-1
    • PD-LI
    • CTLA-4 
      
  • Immune System Modulators 
  • Cancer Vaccines 
  • Oncolytic Virus 
  • Others 
    
• By Disease Type
  
• • Melanoma 
  • Lung Cancer 
  • Blood Cancer 
  • Renal Cell Carcinoma 
  • Prostate Cancer 
  • Bladder Cancer 
  • Others (Breast Cancer, Thyroid Cancer, etc.) 
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:         
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.